Leverage points | Group of stakeholders | Key initiative | Attractiveness for stakeholders* | Potential impact† | Required investment† | Required effort† |
---|---|---|---|---|---|---|
Global appreciation | ||||||
Improve epidemiological and clinical knowledge of RA | U-GP, R-GP, REU, ANDAR | Optimization of RA National Registry | Clearly interesting | Medium | Medium | Medium |
Promote patient’s knowledge about RA | U-GP, R-GP, REU, ANDAR | Dissemination of information on rheumatic symptoms in primary care centres | Clearly interesting | Medium | Low | Low |
U-GP, R-GP, REU, ANDAR | Valorisation of RA and adequate treatment | Likely interesting | Medium | Low | Low | |
Promote GPs’ knowledge about RA | U-GP, R-GP, REU | Regular visits of specialists to primary healthcare centres | Clearly interesting | Medium | Low | Medium |
U-GP, R-GP, REU, PHA | Regular training sessions about RA for GPs | Clearly interesting | Medium | Low | Low | |
Promote fulfilment of biologics guidelines | REU, SPR | Promote successful case reports about biologic treatment | Likely interesting | Medium | Low | Low |
REU, SPR | Promote broader utilization of diagnosis and monitoring tools | Likely interesting | Medium | Low | High | |
HMA, REU | Implement hospital-based research to collect real-world data | Clearly interesting | Medium | Medium | Medium |